Just now, Takeda announcedFiscal Year 2024H1Performance：
As of September 30, 2024,TakedaH1 Total Revenue Approximately23.84 trillion yen(Approximately 16.6 billion USD).Revenue growth at Takeda was 13.4% at actual exchange rates (AER); +5% at constant exchange rates (CER).。
In summary, TakedaStrong performance in the first half of the year, whileRaised the full-year forecast and guidance。
Takeda's growth and marketed product portfolio showed strong performance,Product sales revenue increased by 18.7%(Calculated by CER)，Accounting for 47% of total revenue, reflecting its promising prospects for restoring sustainable income and profit growth in the short term.
FRUZAQLA
According to Takeda's financial report,FruquintinibH1 2024Sold 23.1 billion yen (approximately 151 million US dollars, increased by 12%) ）, which highlights the prospects of the drug andFuture Strong Revenue GrowthThe potential.
Fruquintinib sales exceed expectations, with significant growth in the U.S. market.United States:The market share of 4L+ mCRC reaches 29%, and the market share of 3L+ mCRC reaches 10%;
Following its approval for marketing in the United States in November 2023, fruquintinib has once again expanded its approved scope.Approved for marketing by Japan's Ministry of Health, Labour and Welfare (MHLW) in September 2024, for the treatment of previously treated patients with metastatic colorectal cancer.。
Fruzaqla (fruquintinib) was initially developed byHutchmed Subsidiary Hutchison WhampoaResearch and Development,Is a highly selective VEGFR-1/2/3 kinase inhibitor,Approved in China in September 2018 for the treatment of colorectal cancer. This product was co-developed with Eli Lilly and Company and is marketed under the brand name ELUNATE™.January 2023, Takeda andHutchison WhampoaSign an Exclusive Licensing Agreement, obtainOutside of mainland China, Hong Kong, and Macao, for further development, commercialization, and manufacturingFruquintinibThe exclusive rights of Fruzaqla.
November 2023,FruquintinibIn the United StatesApprovedLaunched for the treatment of previously treated metastatic colorectal cancer,Became the first and only highly selective inhibitor targeting all three VEGF receptor kinases approved in the United States for the treatment of previously treated metastatic colorectal cancer, regardless of the patient's biomarker status.Outlook for Fiscal Year 2024
Takeda CFO Milano Furuta commented:"We are raising our full-year outlook for the fiscal year 2024, reflecting stronger-than-expected performance in the first half and updated annual foreign exchange assumptions."The full-year guidance reflects our intention to increase R&D investment in the second half of the year to support our late-stage product pipeline."We remain confident in achieving sustainable growth through our expansion, product launches, and promising late-stage pipeline. We will continue to drive initiatives to improve our core operating profit margin starting from the fiscal year 2025, aiming to reach our mid-to-low 30% target."
Statement:All articles published on this official account (including original and reprinted articles) are intended to convey more information, with sources and authors clearly attributed. This official account welcomes sharing in friend circles or large groups.Reproduction in any form by media or organizations without authorization is prohibited.。Reprint/Business/Contribution| Contact WeChat15618157102（sum_Gmi）
